PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY RR Barreto; K Patel; C Coombs; N Shah; T Eyre; W Wierda; P Ghia; M Davids; W Jurczak; A Mato;

SEQUOIA 5-YEAR FOLLOW-UP IN ARM C: FRONTLINE ZANUBRUTINIB MONOTHERAPY IN PATIENTS WITH DEL(17P) AND TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA R Dalfeor; CS Tam; P Ghia; M Shadman; T Munir; SS Opat; PA Walker; T Tian; J Hirata; JR Brown;

PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP NN Shah; PL Zinzani; TA Eyre; K Izutsu; AJ Alencar; K Patel; T Munir; DE Tsai; ML Wang; LYGN Presenter;